MX9704629A - Metodo, composiciones y equipos para incrementar la biodisponibilidad oral de agentes farmaceuticos. - Google Patents

Metodo, composiciones y equipos para incrementar la biodisponibilidad oral de agentes farmaceuticos.

Info

Publication number
MX9704629A
MX9704629A MX9704629A MX9704629A MX9704629A MX 9704629 A MX9704629 A MX 9704629A MX 9704629 A MX9704629 A MX 9704629A MX 9704629 A MX9704629 A MX 9704629A MX 9704629 A MX9704629 A MX 9704629A
Authority
MX
Mexico
Prior art keywords
oral
agent
target
bioavailability
enhancing
Prior art date
Application number
MX9704629A
Other languages
English (en)
Inventor
Samuel Broder
Kennteh Duchin
Sami Selim
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/608,776 external-priority patent/US5968972A/en
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of MX9704629A publication Critical patent/MX9704629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se presenta un método para incrementar la biodisponibilidad después de administracion oral de un agente blanco farmacologicamente activo, particularmente un agente antitumoral o bien antineoplásico que presenta una biodisponibilidad limitada a bien inconsistente (por ejemplo paclitaxel, docetaxel o bien etoposido), que comprende la coadministracion oral a un paciente mamífero de un agente blanco y un agente de incremento de la biodisponibilidad oral (por ejemplo ciclosporina A, ciclosporina D, ciclosporina F o bien quetaconazol). El agente de incremento de la biodisponibilidad oral puede administrarse oralmente de 0.5 a 24 horas antes de la administracion oral de una o varías dosis del agente blanco, de manera sustancialmente simultánea con el agente blanco o bien tanto antes como sustancialmente simultáneamente con el agente blanco. Se presentan un método para el tratamiento de pacientes mamíferos que padecen de enfermedades que responden a los agentes blanco con una biodisponibilidad oral limitada, así como formas de dosificacion oral que contiene tales agentes blanco, formas de dosificacion oral de combinacion que contienen los agentes de incremento de la biodisponibilidad y agentes blanco, equipos que contienen formas de dosificacion de agente de incremento de la biodisponibilidad y agente blanco así como informacion de dosificacion para la coadministracion de las mismas.
MX9704629A 1995-10-26 1996-10-24 Metodo, composiciones y equipos para incrementar la biodisponibilidad oral de agentes farmaceuticos. MX9704629A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US707195P 1995-10-26 1995-10-26
US08/608,776 US5968972A (en) 1995-10-26 1996-02-29 Method for increasing the oral bioactivity of pharmaceutical agents
US08/733,142 US6245805B1 (en) 1995-10-26 1996-10-16 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PCT/IB1996/001485 WO1997015269A2 (en) 1995-10-26 1996-10-24 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (1)

Publication Number Publication Date
MX9704629A true MX9704629A (es) 1997-09-30

Family

ID=27358262

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9704629A MX9704629A (es) 1995-10-26 1996-10-24 Metodo, composiciones y equipos para incrementar la biodisponibilidad oral de agentes farmaceuticos.

Country Status (22)

Country Link
US (6) US6245805B1 (es)
EP (1) EP0794794B1 (es)
JP (1) JP3361102B2 (es)
CN (2) CN100335123C (es)
AT (1) ATE311903T1 (es)
AU (1) AU698142B2 (es)
BR (1) BR9607066A (es)
CA (1) CA2205534A1 (es)
CZ (1) CZ202897A3 (es)
DE (2) DE794794T1 (es)
DK (1) DK0794794T3 (es)
ES (1) ES2109899T3 (es)
HK (1) HK1001960A1 (es)
HU (1) HUP9900457A3 (es)
IL (1) IL121160A0 (es)
MX (1) MX9704629A (es)
NO (1) NO321091B1 (es)
NZ (1) NZ324801A (es)
PL (2) PL188281B1 (es)
RU (1) RU2217135C2 (es)
SK (1) SK85997A3 (es)
WO (1) WO1997015269A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1550231A (zh) * 1997-05-27 2004-12-01 �Ϳˡ�ŵ��ҩ�����޹�˾ 给予病人口服紫杉烷类药物的方法和组合物
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU9785698A (en) * 1997-10-02 1999-04-27 Microcide Pharmaceuticals, Inc. Fungal efflux pump inhibitors
BR9912501A (pt) * 1998-06-29 2001-05-02 Los Angeles Childrens Hospital Tratamento de distúrbios hiperproliferativos
DE60030283T2 (de) 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
EP1225956A1 (en) * 1999-10-27 2002-07-31 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
CA2367661A1 (en) * 2000-02-02 2001-08-09 Robert A. Holton Taxane formulations having improved solubility
US6750246B1 (en) 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US20030158097A1 (en) * 2000-03-02 2003-08-21 Norifumi Tanida P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2002363523A1 (en) * 2001-11-07 2003-05-19 Pharmacia Corporation Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
KR20040066921A (ko) * 2001-12-20 2004-07-27 브리스톨-마이어스스퀴브컴파니 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
JP2006514698A (ja) * 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
GB2423928B (en) * 2004-11-16 2008-04-09 Efflux Technology Inc Methods and compositions for treating pain
AU2006304143A1 (en) * 2005-10-14 2007-04-26 Allergan, Inc. Prevention and treatment of drug-associated ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
MX2009013663A (es) * 2007-06-22 2010-01-27 Scidose Llc Formulacion solubilizada de docetaxel sin tween 80.
US20090111736A1 (en) * 2007-10-29 2009-04-30 Sri International Orally-Absorbed Solid Dose Formulation for Vancomycin
CN101559059B (zh) * 2008-04-16 2012-12-05 北京万全阳光医学技术有限公司 一种含有盐酸阿米洛利的药物组合物及其制备方法
US20090318561A1 (en) * 2008-06-23 2009-12-24 Mutual Pharmaceutical Company, Inc. Colchicine products, method of manufacture, and methods of use
US20110207660A1 (en) * 2008-08-07 2011-08-25 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US7820681B1 (en) 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
US20110046228A1 (en) * 2009-08-20 2011-02-24 Mutual Pharmaceutical Company, Inc. Methods for administration of colchicine with grapefruit juice
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN102970990A (zh) 2010-05-03 2013-03-13 帝国制药美国公司 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN107843966B (zh) 2016-09-18 2021-05-04 中芯国际集成电路制造(上海)有限公司 用于装配微透镜阵列组件的方法和***
CN106822085B (zh) * 2016-12-17 2020-03-17 浙江省人民医院 表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途
SG11202105221XA (en) * 2018-11-21 2021-06-29 Elevar Therapeutics Inc Pharmaceutical methods

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118493A (en) 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
ATE95193T1 (de) 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
JP2525478B2 (ja) 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5208238A (en) 1989-06-19 1993-05-04 Burroughs Wellcome Company Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
GB8914040D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914060D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8926715D0 (en) 1989-11-28 1990-01-17 Haessle Ab Improvements relating to the administration of pharmaceutical agents
AU665341B2 (en) 1990-12-18 1996-01-04 Wellcome Foundation Limited, The Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
JP2783680B2 (ja) 1991-01-11 1998-08-06 ラボラトワール、グラクソ、ソシエテ、アノニム アクリジン誘導体
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
CA2129288C (en) * 1993-08-17 2000-05-16 Jerzy Golik Phosphonooxymethyl esters of taxane derivatives
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
FR2718963B1 (fr) 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
US5616330A (en) * 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
WO1997027855A1 (en) 1996-01-31 1997-08-07 Bristol-Myers Squibb Company A method of making pharmaceutically active taxanes orally bioavailable
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
ATE311903T1 (de) 2005-12-15
NO972968D0 (no) 1997-06-25
CN100335123C (zh) 2007-09-05
PL321791A1 (en) 1997-12-22
US20050238634A1 (en) 2005-10-27
CZ202897A3 (cs) 1998-03-18
CN1490048A (zh) 2004-04-21
JP3361102B2 (ja) 2003-01-07
NO321091B1 (no) 2006-03-13
PL192544B1 (pl) 2006-11-30
HUP9900457A3 (en) 2001-04-28
IL121160A0 (en) 1997-11-20
CA2205534A1 (en) 1997-05-01
US20030069301A1 (en) 2003-04-10
WO1997015269A3 (en) 1997-07-31
US20070060635A1 (en) 2007-03-15
US20040176439A1 (en) 2004-09-09
US6610735B2 (en) 2003-08-26
EP0794794A4 (en) 2000-03-01
DE794794T1 (de) 1998-03-12
WO1997015269A2 (en) 1997-05-01
AU698142B2 (en) 1998-10-22
DE69636531D1 (de) 2006-10-19
US6245805B1 (en) 2001-06-12
US7041640B2 (en) 2006-05-09
HUP9900457A2 (hu) 1999-06-28
DK0794794T3 (da) 2006-04-18
NZ324801A (en) 1999-05-28
CN1119146C (zh) 2003-08-27
EP0794794B1 (en) 2005-12-07
NO972968L (no) 1997-07-23
PL188281B1 (pl) 2005-01-31
ES2109899T1 (es) 1998-02-01
RU2217135C2 (ru) 2003-11-27
SK85997A3 (en) 1998-06-03
US20020058616A1 (en) 2002-05-16
JPH10509741A (ja) 1998-09-22
US6818615B2 (en) 2004-11-16
DE69636531T2 (de) 2006-12-07
CN1173817A (zh) 1998-02-18
EP0794794A1 (en) 1997-09-17
AU1205697A (en) 1997-05-15
HK1001960A1 (en) 1998-07-24
BR9607066A (pt) 2002-12-10
ES2109899T3 (es) 2006-05-01

Similar Documents

Publication Publication Date Title
IL121160A0 (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
DE1001772T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
BG101118A (en) Therapeutical compounds
BG104620A (en) Oral pharmaceutical extended release dosage form
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
FI962735A0 (fi) 2-hydroksi-5-fenylatsobensoehapon johdannaisten käyttö paksusuolen syövän kemialliseen ehkäisyyn ja kemoterapeuttisena aineena
BG105173A (en) Novel salt form of pantoprazole
ATE292453T1 (de) Antivirale arznei
ATE273693T1 (de) Proteinhaltige arzneimittel
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
AU4955200A (en) A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
HUP0003546A2 (hu) Kompozíciók taxánok orális adagolására embereknek
NO20001828L (no) Metode for Õ forhindre nefrotoksisitet forÕrsaket av cyklosporiner og tacrolimus
HK1079688A1 (en) Statin product for enhancing cognitive maintenance
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
GEP20043377B (en) Pharmaceutical Complex
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
HUP9800623A2 (hu) (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására
NZ516026A (en) Oral administration of taxanes to human patients using cyclosporins as bioavailability-enhancing agents
UA79424C2 (en) Use of fsh for treatment of infertility in women

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees